UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
Date
of
Report (Date of earliest event reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
|
State
of New York
|
1-10113
|
11-0853640
|
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
|
of
Incorporation)
|
|
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
o Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
Item
8.01 Other
Events
On
October
13, 2008
we
announced top-line results from Study AP-ADF-111 (Study 111) entitled "A Phase
II, Single-Center, Randomized, Double-Blind, Assessment of the Abuse Liability
of Acurox™ (oxycodone HCl and niacin) Tablets in Subjects with a History of
Opioid Abuse." Study 111 results demonstrate that Acurox™ Tablets are disliked
compared to oxycodone HCl tablets alone when excess doses are swallowed. These
results are statistically significant based on the dislike/like scores (p =
.033), the primary measure of abuse deterrence potential for the
study.
We
are
parties to a License, Development and Commercialization Agreement with King
Pharmaceuticals Research and Development, Inc. (“King”), a wholly-owned
subsidiary of King Pharmaceuticals, Inc. dated as of October 30, 2007, as
amended, pursuant to which, among other things, we have licensed Acurox™ Tablets
to King in the United States, Canada and Mexico.
A
copy of
the press release issued by us jointly with King Pharmaceuticals, Inc. with
respect to the above is being furnished as Exhibit 99.1.
Item
9.01 Financial
Statements and Exhibits
|
Exhibit Number
|
|
Description
|
| |
|
|
|
99.1
|
|
Joint
Press Release of the Registrant and King Pharmaceuticals, Inc. dated
October 13, 2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
ACURA
PHARMACEUTICALS, INC.
|
| |
|
|
By:
|
/s/
Peter Clemens
|
| |
Peter
A. Clemens
|
| |
Senior
Vice President & Chief Financial
Officer
|
Date: October
13, 2008
EXHIBIT
INDEX
|
|
|
Description
|
| |
|
|
|
|
|
Joint
Press Release of the Registrant and King Pharmaceuticals, Inc. dated
October 13, 2008.
|